pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
467
stories
Aug 11, 26
Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
fiercebiotech
Aug 11, 26
Building Resilience for the Future of Biopharma Innovation
fiercebiotech
Aug 11, 26
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
biospace
Aug 11, 26
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
biospace
Aug 11, 26
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
biospace
Aug 11, 26
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
fiercebiotech
Aug 10, 26
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
Aug 10, 26
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
biospace
Aug 10, 26
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
Aug 10, 26
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
Aug 10, 26
Opinion: We prepared for Ebola — but not this Ebola
stat
Aug 10, 26
Opinion: We prepared for Ebola — but not this Ebola
stat
Aug 10, 26
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
fiercebiotech
Aug 10, 26
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
Aug 10, 26
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
Aug 10, 26
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
fiercebiotech
Aug 10, 26
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
Aug 10, 26
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
biospace
Aug 7, 26
Is the biotech capital of the world moving?
stat
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 7, 26
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
fiercebiotech
Aug 6, 26
BioVie shares halve on murky Parkinson’s disease readout
biospace
Aug 6, 26
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
Aug 6, 26
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
fiercebiotech
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Aug 5, 26
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms
fda press
Aug 5, 26
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
Aug 5, 26
STAT+: Could poop pills be the next treatment for food allergies?
stat
← prev
page 7 of 16
next →
